Sculptor Capital
PRDS

Sculptor Capital’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Sculptor Capital’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-242,000
Closed -$2.41M – 1241
2021
Q3 		$2.41M Hold
242,000
– – 0.02% 449
2021
Q2 		$2.42M Buy
242,000
+72,000
+42% +$723K 0.02% 474
2021
Q1 		$1.69M Buy
+170,000
New +$1.76M 0.01% 455

Other funds holding PRDS

Foresite Capital Management V
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Foresite Capital Opportunity Management V
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Frazier Management
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
EcoR1 Capital
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Arena Capital Advisors
Arena Capital Advisors Los Angeles, California $200M AUM 6.35% 1-Year Est. Return
Platinum Investment Management
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
JCM
JS Capital Management New York $223M AUM 104.76% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

Sculptor Capital's PRDS Position: Q4 2021 in Review

Sculptor Capital sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q4 2021, closing a stake of 242,000 shares — an estimated $2.41M sold.

Sculptor Capital first reported a position in PRDS in Q1 2021 and held it in 3 quarters. The position peaked at $2.42M in Q2 2021. 41 funds tracked by Wall St. Rank hold PRDS as of Q4 2021.

  • Sculptor Capital reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Sculptor Capital sold 242,000 Pardes Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $2.41M.
  • Sculptor Capital first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Sculptor Capital's Pardes Biosciences, Inc. Common Stock position peaked at $2.42M in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q4 2021.

Based on Sculptor Capital's 13F filing for Q4 2021, filed 11 Feb 2022.